Achieve Life Sciences (NASDAQ:QUIT – Get Free Report) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.
Other analysts have also recently issued research reports about the company. Zacks Research started coverage on Achieve Life Sciences in a research report on Tuesday, November 10th. They set a “hold” rating for the company. Weiss Ratings started coverage on shares of Achieve Life Sciences in a research note on Wednesday. They set a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Achieve Life Sciences currently has an average rating of “Reduce”.
View Our Latest Research Report on QUIT
Achieve Life Sciences Stock Performance
Shares of NASDAQ:QUIT opened at $6.32 on Friday. The company has a current ratio of 10.49, a quick ratio of 10.49 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $695.39 million, a PE ratio of -4.08 and a beta of 2.42. Achieve Life Sciences has a 52-week low of $2.62 and a 52-week high of $8.64.
About Achieve Life Sciences
Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products. Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.
See Also
- Five stocks we like better than Achieve Life Sciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
